Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

Conclusions:
The current analysis highlights the limited value of second-line chemotherapy after a first-line GP combination in aBTC. While waiting for effective biologic agents in this setting, ongoing randomized trials will identify the optimal second-line chemotherapy regimen and validate prognostic factors for individual patient management.

Source: Epidemiologic Perspectives and Innovations - December 23, 2015 Category: Epidemiology Authors: Lorenzo FornaroCaterina VivaldiStefano CeredaFrancesco LeoneGiuseppe AprileSara LonardiNicola SilvestrisDaniele SantiniMichele MilellaChiara CaparelloGianna MusettiniGiulia PasquiniAlfredo FalconeGiovanni BrandiIsabella SperdutiEnrico Vasileon behalf of t Source Type: research